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The MPCS Plug Maker is a microcapillary-based protein-crystallization system
for generating diffraction-ready crystals from nanovolumes of protein. Crystal-
lization screening using the Plug Maker was used as a salvage pathway for
proteins that failed to crystallize during the initial observation period using the
traditional sitting-drop vapor-diffusion method. Furthermore, the CrystalCards
used to store the crystallization experiments set up by the Plug Maker are shown
be a viable container for long-term storage of protein crystals without a
discernable loss of diffraction quality with time. Use of the Plug Maker with
SSGCID proteins is demonstrated to be an effective crystal-salvage and storage
method.
1. Salvaging protein targets
The Seattle Structural Genomics Center for Infectious Disease
(SSGCID) seeks to determine the molecular structures of bacterial
proteins thought to be good targets for drug therapies, with a target of
75 structures per year over ﬁve years. These protein targets arrive at
the crystallization core facility at Emerald BioStructures in highly
puriﬁed and concentrated form as frozen aliquots. A schematic of the
workﬂow used in this study is shown in Fig. 1. 10–15 new targets
arrive at the facility each week and are immediately screened
for crystallization using traditional sitting-drop vapor diffusion.
Following the strategy proposed by Newman et al. (2005), all targets
are screened against two 96-condition screens, JCSG+ (Emerald
BioSystems) and PACT Premier (Molecular Dimensions), giving 192
unique conditions. The experiments are monitored for four weeks
Figure 1
Workﬂow schematic for the salvage study.and any crystals that form enter an optimization pathway that
includes testing for protein crystal diffraction, subsequent crystal
optimization and structure determination. Inevitably, there are
protein targets that produce no crystals within four weeks or fail in
the optimization pathways. Typically, these targets are retired from
active observation to open space for the next set of incoming targets.
Within the Emerald BioStructures crystallization core facility, stra-
tegies have been utilized to attempt to salvage the structure deter-
mination of retired proteins. Such salvage pathways have included
limited proteolysis (McPherson et al., 2004) and exogenous nuclea-
tion (D’Arcy et al., 2003; Thakur et al., 2007), although both had very
limited success for the required effort involved.
With close to 900 retired protein targets currently available for
salvage, the MPCS (Microcapillary Protein Crystallization System)
Plug Maker (Emerald BioSystems) was used to thoroughly re-screen
a small set of retired proteins. The plug-based microﬂuidic technology
encompassed in the Plug Maker is able to thoroughly screen crys-
tallization conditions by quickly and automatically generating con-
centration gradients for each condition that is screened. Details of
the Plug Maker and its underlying technology have been published
previously (Gerdts et al., 2008, 2010; Li et al., 2006; Zheng et al., 2003,
2005). Using this technology, as many as 800 20 nl crystallization
experiments can be set up in one CrystalCard (Emerald BioSystems;
Fig. 2) using as little as 5 ml protein sample. Furthermore, although
they only use up  10 nl of protein each, the experiments are large
enough to produce diffraction-ready crystals (50–200 mm per side)
that can be examined in situ or extracted from the peel-apart
CrystalCard (Gerdts et al., 2008, 2010; Yadav et al., 2005).
The JCSG+ screen used for the initial trials set up for SSGCID
targets arose from data mining conducted by the Joint Center for
Structural Genomics, which identiﬁed 96 conditions in commercial
screens that had been most successful in crystallizing proteins
(Newman et al., 2005; Page & Stevens, 2004). 16 of these conditions
were taken from Wizard Screens I and II (Emerald BioSystems) in
order to compose the MPCS Sweet 16 Screen (Table 1).
Protein targets to be salvaged were screened against all or a
portion of the MPCS Sweet 16 Screen based on the availability of
remaining protein. No special criteria were used to select the targets
other than that they were listed in our tracking spreadsheet as having
failed to crystallize in either of the two standard vapor-diffusion trials
during the initial four-week screening period. Subsequent to their
selection for MPCS screening,the retired targets were re-examined in
their original vapor-diffusion plates or selected for additional vapor-
diffusion trials for other reasons and ended up crystallizing sometime
between two and six months after initial screening. These samples
were still included in this analysis because the comparison to the
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Figure 2
Image of a CrystalCard showing the two microcapillary channels.
Table 1
Concentrated conditions composing the MPCS screen (MPCS Sweet 16).
MPCS
Screen
No.
Wizard
Full No. JCSG+ At 100 mM At 200 mM
1 1 A-7 30%(w/v) PEG 8000 CHES pH 9.5 None
2 2 E-3 20%(v/v) 2-propanol HEPES pH 7.5 NaCl
3 6 A-2 30%(w/v) PEG 3000 Citrate pH 5.5 None
49 E - 8 1 . 5 M (NH4)2HPO4 Acetate pH 4.5 None
5 14 E-1 1.4 M sodium citrate Cacodylate pH 6.5 None
6 17 D-4 40%(w/v) PEG 8000 Acetate pH 4.5 Li2SO4
7 31 C-1 30%(w/v) PEG 8000 Phosphate–citrate pH 4.2 NaCl
8 39 A-6 30%(w/v) PEG 1000 Phosphate–citrate pH 4.2 Li2SO4
9 47 E-4 2.52 M (NH4)2SO4 Tris pH 8.5 Li2SO4
10 49 C-7 20%(w/v) PEG 3000 Acetate pH 4.5 Zn(OAc)2
11 51 D-6 30%(w/v) PEG 8000 Tris pH 8.5 MgCl2
12 52 E-2 3.0 M (NH4)2SO4 Cacodylate pH 6.5 NaCl
13 59 E-7 20%(v/v) 2-propanol Cacodylate pH 6.5 Zn(OAc)2
14 82 E-12 20%(w/v) PEG 8000 Imidazole pH 8.0 None
15 88 E-6 30%(w/v) PEG 3000 Imidazole pH 8.0 Zn(OAc)2
16 91 B-8 20%(w/v) PEG 8000 Tris pH 7.0 MgCl2
Figure 3
Pictures of crystals obtained in batch-under-oil-style microﬂuidic experiments in the CrystalCards. The microcapillary width in all pictures is 200 mm. (a) MyavA01582cA1;
(b) MyavA01582aA1; (c) MyavA01566cA1; (d) MyavA00213aA1; (e) MysmA01566cA1; (f) MyavA01582cA1; (g) MythA00746aA1; (h) GilaA01434aA1initial screening for retired targets remains valid (Table 3). One of the
protein samples was not set up in vapor-diffusion trials because the
volume delivered was inadequate and thus went directly to MPCS.
Crystallization experiments were set up in CrystalCards using the
Plug Maker instrument. These experiments are analogous to batch
crystallization, in which the crystallization reagents are combined in
a drop (plug) surrounded by an oil and this initial condition is not
expected to change signiﬁcantly over time (see crystal pictures in
Fig. 3). In this system, each plug is separated by a small volume
of inert perﬂuorinated oil (Fluorinert FC-40, Sigma–Aldrich). The
CrystalCard contains two separate microcapillaries and a thorough
gradient of as many as 12 different crystallization conditions can be
screened in each microcapillary, covering a wide range of crystal-
lization phase space.
2. Storing protein crystals
Long-term storage of protein crystals at room temperature may be
useful for the production of protein crystals for future research
(ligand soaking) and may be useful owing to a lack of immediate
access to X-ray data collection. Using traditional sitting-drop vapor
diffusion or batch-under-oil techniques, protein-crystal storage can be
difﬁcult owing to evaporation of the crystallization drop. A long-term
study of crystal stability in CrystalCards has shown that crystal-
lization experiments inside CrystalCards can be stored without
measurable evaporation and without meaningful loss of protein
crystal diffraction quality. Crystals of BrabA.00113a.A1, an infectious
disease target from SSCGID, were grown at the same time inside six
CrystalCards and were subsequently examined using in situ X-ray
diffraction by mounting the CrystalCard on the goniometer (Fig. 4;
Gerdts et al., 2008; Yadav et al., 2005) periodically from April to
December 2010. While not quantiﬁed, the crystals appeared to be
unchanged and showed no obvious degradation of protein crystal
diffraction quality over the course of eight months (Fig. 5). Further-
more, a 2.6 A ˚ resolution data set was collected from one of the
protein targets salvaged in this study (MysmA00391bA1/3C) after the
crystals had been stored in the CrystalCard for approximately ﬁve
months (Table 2).
3. Materials and methods
3.1. Crystallization screening conditions
The similarity of microcapillary crystallization to batch crystal-
lization makes it advantageous to start with crystallization solutions
at higher component concentrations than are found in commercial
sparse-matrix screens; thus, when running a concentration gradient of
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Figure 4
Picture of a CrystalCard mounted on a goniometer for in situ diffraction
experiments.
Table 2
Data-collection statistics.
Values in parentheses are for the highest of 20 resolution shells
MysmA.00391.bA1/3C MysmA.01566.cA1
Space group P21 R3/R32
Unit-cell parameters (A ˚ ,  ) a = 57.6, b = 95.6,
c = 115.3,   = 99.6
a = b = 87.8,
c = 183.9
Wavelength (A ˚ ) 1.5418 1.5418
Resolution range (A ˚ ) 50–2.8 (2.90–2.80) 50–2.6 (2.69–2.60)
No. of unique reﬂections 30844 (3076) 16285 (1623)
Multiplicity 3.5 (3.4) 2.7 (2.7)
Completeness 99.6 (100) 99.6 (99.9)
Rmerge† 0.13 (0.48) 0.13 (0.49)
Mean I/ (I) 6.94 (2.66) 6.87 (2.2)
† Rmerge =
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.
Figure 5
Comparison of in situ diffraction of BrabA.00113a.A1 cystals after long-term storage. Diffuse X-ray scatter is a result of the plastic material of the CrystalCard.a crystallization condition against a target protein sample the
resulting plugs in the gradient will cover a wider crystallization space.
During development of the MPCS Plug Maker system, custom
versions of Wizard Screens I and II were designed in which the same
reagents were used but at proportionally higher concentrations.
Using the 16 conditions common to both the Wizard and JCSG+
screens would allow us to compare the microcapillary results with
those of the initial vapor-diffusion trials; these conditions were
dubbed the ‘MPCS Sweet 16 Screen’ (see Table 1).
3.2. MPCS parameters
The protein samples were set up using the Plug Maker hybrid
protocol. Gradients of conditions 1–8 and 9–16 of the Sweet 16
Screen were run in channels one and two, respectively. Approxi-
mately 5 ml protein sample was required to screen all 16 conditions.
3.3. CrystalCard storage
CrystalCards were stored in standard plastic microscope slide
boxes (VWR) with a small amount of water added to keep them
humidiﬁed. The boxes were kept at 289 K.
3.4. Diffraction testing
For in situ diffraction screening at room temperature, CrystalCards
were mounted on the goniometer using a special clip (Fig. 4). The
CrystalCards were oriented with the thin backing of the card facing
the detector and the plug containing the crystal was aligned in the
beam. Rotation of the card in the ! axis is limited to approximately
 15  from0  becauseofinterferencewiththebeamstopaswellasthe
increasing thickness of the card that the X-ray beam must penetrate
when the card is not perpendicular to the beam. A few 30 s/0.5  test
images were collected within this range and examined for protein
diffraction. If no obvious diffraction was noted a salt test was
performed.
3.5. Salt test
With the card mounted and aligned as above, the detector was
moved in to 50 mm and the 2  axis moved out to 45 . A wedge of
1 /10 simages at least 15  wide was collected and ifno small-molecule
reﬂections were observed the crystal was characterized as ‘not salt’.
4. Results and discussion
Microﬂuidic salvage efforts were attempted on 34 targets. 23
produced crystals or crystal-like objects. Through in situ X-ray
diffraction screening eight of these showed obvious protein diffrac-
tion patterns, and complete data sets to  2.6 A ˚ resolution were
collected for two targets from crystals harvested directly from the
CrystalCards (Table 2). Because the crystals screened at room
temperature may have sustained radiation damage, the data sets were
collected at 100 Kusing different crystals from the same cards. Of the
remaining crystals, 11 were characterized as‘likely protein’ owing to a
laboratory communications
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Table 3
Summary of MPCS crystallization results.
MPCS CrystalCard in situ diffraction screening and data collection
SSGCID target protein MPCS sample No. MPCS crystals† Protein diffraction‡ Likely protein Not salt Salt
Vapor-diffusion crystals
in retired trays§
AnphA.00481.aA1 1
AnphA.00462.aA1 2
BaheA.00227.aA1 3
BaheA.01161.aA1/3C 4
EnhiA.01533.aA1 5 * X
GilaA.01434.aA1 6 * X
LedoA.00425.aAG11 7 * * *
MyavA.00213.aA1 8 * XX *
MyavA.00754.aA1 9 * XX
MyavA.00814.aA1 10
MyavA.00937.aA1 11 * X *
MyavA.01097.hA1 12
MyavA.01097.iA1 13 * * *
MyavA.01188.aA1 14 * X
MyavA.01212.aA1 15 * XX *
MyavA.01326.lA1 16
MyavA.01379.aA1 17 * X *
MyavA.01530.cA1 18 * X *
MyavA.01549.bA1 19
MyavA.01582.aA1 20 * XX PDB 3qlj
MyavA.01582.cA1 21 * XX *
MyavA.01625.aA1 22 * X *
MyavA.01649.cA1 23 * X
MyavA.10520.bA1 24 * X
MyavA.17065.aA1 25
MyleA.00778.aA1 26 * X *
MyleA.01155.aA1 27
MypaA.00249.aA1 28
MysmA.00337.bA1 29 * *
MysmA.00391.bA1/3C 30 * XXX *
MysmA.01263.bA1 31 * *
MysmA.01566.bA1 32 * X
MysmA.01566.cA1 33 * XXX *
MythA.00746.aA1 34 * XX *
Totals 34 23 8 11 2 2 14
† An asterisk indicates the presence of crystals. ‡ X, evidence of protein crystal diffraction in situ in the CrystalCard; XX, clear evidence of protein crystal diffraction in situ in the
CrystalCard; XXX, complete X-ray diffraction data set collected from a crystal extracted from the peeled-apart CrystalCard. § An asterisk indicates the presence of crystals. A
structure was deposited for MyavA.01582.aA1 with PDB code 3qlj.few very low-resolution reﬂections close to the beam stop, two were
characterized as ‘not salt’ after failing the salt test (see x3) and two
were conﬁrmed as being salt crystals (Table 3).
The initial vapor-diffusion screening of SSGCID samples against
only two 96-condition screens is minimal and has allowed the crys-
tallization group to achieve the annual goals outlined in the goals of
the SSGCID. Screening these same samples against a larger number
of sparse-matrix screens may have resulted in crystals for a larger
percentage of samples, but would come with the additional burden
of more trials to set up, monitor and store, and a greater cost of
consumables. Using the capabilities of the Plug Maker to screen a
wide variety of concentrations of just 16 crystallization screening
conditions has resulted in two high-resolution data setsand legitimate
crystallization leads for many previously retired targets. While all of
the vapor-diffusion crystals reported here appeared after four weeks,
many of the MPCS crystals appeared in the CrystalCards within days.
The results of these preliminary MPCS experiments are very
encouraging. Although nominally using a screen of only 16 condi-
tions, the actual number of unique conditions is the number of plugs
in the CrystalCard (up to  800) because each crystallization solution
is run as a gradient. The ability to obtain crystallization leads, protein
crystal diffraction and full diffraction data sets using less than 10 ml
protein sample, and with a success rate comparable to standard
crystallization methods, represents a large saving in effort and indi-
cates that efﬁcient microﬂuidic scanning of protein and crystallization
condition concentrations in initial crystallization trials using the
MPCS Plug Maker can be a highly effective means of producing
protein crystals.
In addition to soluble proteins, the Plug Maker may prove to be
useful for crystallizing nucleic acids and membrane proteins, both of
which represent special challenges. While preliminary experiments
have shown that membrane proteins solubilized with some detergents
form plugs normally, neither nucleic acids nor membrane proteins
have been tested extensively by us. Experiments are planned to more
thoroughly investigate this and the results of these experiments will
be reported in due course.
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